SDR39U1: A promising drug target in the Short Chain Dehydrogenase/Reductase Family 39U

Target Name: SDR39U1

NCBI ID: G56948

SDR39U1

SDR39U1: A promising drug target in the Short Chain Dehydrogenase/Reductase Family 39U

The Short Chain Dehydrogenase/Reductase Family 39 (SCDR39) is a gene family that has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. One of the known members of this family is SDR39U1, which is a transcript variant of SCDR39. In this article, we will explore the potential of SDR39U1 as a drug target and its underlying biology.

SDR39U1 function

SDR39U1 is a member of the SCDR39 gene family, which encodes a protein involved in the detoxification of xenobiotics and other harmful substances. The SCDR39 gene family has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SDR39U1 is a 21-kDa protein that is expressed in various tissues and cells in the body. It is highly conserved and has a similar structure to other members of the SCDR39 gene family. SDR39U1 functions as a short chain dehydrogenase (SCDH), which is involved in the detoxification of xenobiotics and other harmful substances.

SDR39U1 has been shown to play a crucial role in the detoxification of xenobiotics, such as polychlorinated biphenyls (PCBs) and polycyclic aromatic hydrocarbons (PAHs). These substances are known to be toxic to human health and have been linked to various diseases, including cancer, neurodegenerative diseases, and cardiovascular disorders.

In addition to its role in detoxification, SDR39U1 has also been shown to play a role in cell signaling. It has been shown to be involved in the regulation of cell growth, apoptosis, and inflammation.

SDR39U1 as a drug target

SDR39U1 has been identified as a potential drug target due to its involvement in the detoxification of xenobiotics and its role in cell signaling. Several studies have shown that inhibiting SDR39U1 activity can lead to the inhibition of various cellular processes that are associated with the development of various diseases, including cancer, neurodegenerative diseases, and cardiovascular disorders.

One of the known drug targets associated with SDR39U1 is the production of polycyclic aromatic hydrocarbons (PAHs). PAHs are known to be generated from the detoxification of xenobiotics, including those that are toxic to human health. SDR39U1 has been shown to play a crucial role in the detoxification of these xenobiotics, and inhibiting its activity has been shown to be effective in reducing the production of PAHs.

Another potential drug target associated with SDR39U1 is the regulation of cell apoptosis. SDR39U1 has been shown to play a role in the regulation of cell apoptosis, which is a natural process that helps eliminate damaged or dysfunctional cells.

In addition to its potential drug targets, SDR39U1 has also been shown to have potential as a biomarker. The detection of SDR39U1 expression has been shown to be associated with the development of various diseases, including cancer, neurodegenerative diseases, and cardiovascular disorders.

Conclusion

SDR39U1 is a transcript variant of the Short Chain Dehydrogenase/Reductase Family 39 that has been shown to play a crucial role in the detoxification of xenobiotics and

Protein Name: Short Chain Dehydrogenase/reductase Family 39U Member 1

Functions: Putative NADP-dependent oxidoreductase

The "SDR39U1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDR39U1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets